首页> 外文期刊>Archivum immunologiae et therapiae experimentalis >Soluble TNF-alpha receptor I encoded on plasmid vector and its application in experimental gene therapy of radiation-induced lung fibrosis.
【24h】

Soluble TNF-alpha receptor I encoded on plasmid vector and its application in experimental gene therapy of radiation-induced lung fibrosis.

机译:质粒载体上编码的可溶性TNF-α受体I及其在放射性肺纤维化实验基因治疗中的应用。

获取原文
获取原文并翻译 | 示例
           

摘要

Post-radiation inflammatory reaction leads to an irreversible pulmonary fibrosis which may cause lethal respiratory insufficiency. Pathological inflammatory and fibrotic changes might be attenuated by inhibiting tumour necrosis factor (TNF)-alpha activity using TNF-alpha soluble receptors. Thus, an experimental antifibrotic gene therapy with the plasmid vector encoding a mouse soluble receptor I for TNF-alpha (psTNFR-I) was assessed. Soluble TNFR-I encoding gene was cloned into pcDNA3.1 plasmid. The ability of psTNFR-I expressing vector to transfect cells, and its biological activity in vitro and in vivo were examined by PCR, RT-PCR, MTT assay and ELISA. The C57Bl/6J mice received single intramuscular injection of psTNFR-I, conjugated with polyetylenimine (PEI) 25 kDa, equally divided to both hind legs, 3 days before irradiation (20 Gy, Co60), and either a single injection or ten injections once a week after irradiation. The data proved the effectiveness of psTNFR-I product to neutralise TNF-alpha activity in vitro. The in vivo plasmid incorporation and maintenance was confirmed. Measurements of plasma soluble TNFR-I levels showed that the in vivo gene transfer was effective. PEI was found to enhance transfection efficiency in vivo. The psTNFR-I/PEI complexes caused no toxicity in the transfected mice. C57Bl/6J mice that received prolonged psTNFR-I/PEI injections developed lethal fibrotic syndrome and died 8 weeks later than the mice treated with a double plasmid injection and the control mice treated with a control plasmid. Sequential administration of soluble TNFR-I by a nonviral, intramuscular gene transduction in the early and late post-radiation inflammatory phase prolonged survival of irradiated mice and attenuated the symptoms of lung fibrosis. The psTNFR-I gene transduction may provide a safe and simple method to partially neutralise TNF-alpha activity and prevent radiation-induced lung injury.
机译:放射后炎症反应导致不可逆的肺纤维化,可能导致致命的呼吸功能不全。通过使用TNF-α可溶性受体抑制肿瘤坏死因子(TNF)-α活性,可以减轻病理性炎症和纤维化改变。因此,评估了使用编码TNF-α的小鼠可溶性受体I(psTNFR-1)的质粒载体的实验性抗纤维化基因疗法。将可溶性TNFR-1编码基因克隆到pcDNA3.1质粒中。通过PCR,RT-PCR,MTT测定和ELISA检查了表达psTNFR-1的载体转染细胞的能力及其在体内和体外的生物学活性。 C57Bl / 6J小鼠单次肌肉注射psTNFR-1,与25kDa的聚乙烯亚胺(PEI)结合,在照射前3天(20 Gy,Co60)平均分为后腿,一次或十次照射后一周。数据证明了psTNFR-1产物在体外中和TNF-α活性的有效性。证实了体内质粒的掺入和维持。血浆可溶性TNFR-1水平的测量表明体内基因转移是有效的。发现PEI增强体内转染效率。 psTNFR-1 / PEI复合物在转染的小鼠中未引起毒性。接受延长的psTNFR-1 / PEI注射的C57Bl / 6J小鼠发生致命的纤维化综合征,并且比用双质粒注射治疗的小鼠和用对照质粒治疗的对照小鼠晚8周死亡。在放射后炎症阶段的早期和晚期,通过非病毒性肌内基因转导顺序施用可溶性TNFR-1,可延长辐照小鼠的生存期,并减轻肺纤维化的症状。 psTNFR-1基因转导可提供一种安全,简单的方法,以部分中和TNF-α活性并预防辐射诱发的肺损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号